


## Supporting Information


**Iron oxide–based nanovector for tumor targeted siRNA delivery in an orthotopic hepatocellular carcinoma xenograft mouse model**

Kui Wang, Forrest M. Kievit, Jonathan G. Sham, Mike Jeon, Zachary R. Stephen, Arvind

Bakthavatsalam, James O. Park, and Miqin Zhang\*



**Figure S1.** Evaluation of siRNA binding on NP using the gel retardation assay. Agarose gel images of naked siRNA, NP, NP-siRNA-PC3 Ab, naked siRNA with heparin, and NP-siRNA-GPC3 Ab with heparin.



**Figure S2.** Fluorescence microscopy images showing biodistribution of NP-siRNA-GPC3 Ab in liver, kidney, spleen, and lung *in vivo* at 120 hr post injection. Scale bars represent 20  $\mu\text{m}$ . No NP-siRNA-GPC3 Ab (red) was visible.